JP2010518871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518871A5 JP2010518871A5 JP2009551284A JP2009551284A JP2010518871A5 JP 2010518871 A5 JP2010518871 A5 JP 2010518871A5 JP 2009551284 A JP2009551284 A JP 2009551284A JP 2009551284 A JP2009551284 A JP 2009551284A JP 2010518871 A5 JP2010518871 A5 JP 2010518871A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- fusion polypeptide
- domain
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 230000004927 fusion Effects 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 7
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 6
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 108091008605 VEGF receptors Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 4
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 3
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 206010003445 Ascites Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- RRAWMVYBOLJSQT-ABZYKWASSA-N (2r,3s)-5-[6-amino-8-(pyren-2-ylamino)purin-9-yl]-2-(hydroxymethyl)oxolan-3-ol Chemical compound C=1C(C2=C34)=CC=C3C=CC=C4C=CC2=CC=1NC1=NC=2C(N)=NC=NC=2N1C1C[C@H](O)[C@@H](CO)O1 RRAWMVYBOLJSQT-ABZYKWASSA-N 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 102000012545 EGF-like domains Human genes 0.000 claims 1
- 108050002150 EGF-like domains Proteins 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89176907P | 2007-02-27 | 2007-02-27 | |
| US60/891,769 | 2007-02-27 | ||
| PCT/IB2008/000901 WO2008132568A2 (en) | 2007-02-27 | 2008-02-27 | Fusion proteins binding to growth factors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014042371A Division JP5952847B2 (ja) | 2007-02-27 | 2014-03-05 | 成長因子と結合する融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518871A JP2010518871A (ja) | 2010-06-03 |
| JP2010518871A5 true JP2010518871A5 (enExample) | 2011-04-14 |
| JP5564268B2 JP5564268B2 (ja) | 2014-07-30 |
Family
ID=39795468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551284A Active JP5564268B2 (ja) | 2007-02-27 | 2008-02-27 | 成長因子と結合する融合タンパク質 |
| JP2014042371A Active JP5952847B2 (ja) | 2007-02-27 | 2014-03-05 | 成長因子と結合する融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014042371A Active JP5952847B2 (ja) | 2007-02-27 | 2014-03-05 | 成長因子と結合する融合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10259860B2 (enExample) |
| EP (1) | EP2126092B1 (enExample) |
| JP (2) | JP5564268B2 (enExample) |
| KR (1) | KR101220245B1 (enExample) |
| CN (2) | CN108546301B (enExample) |
| AU (1) | AU2008243928B2 (enExample) |
| CA (1) | CA2679658C (enExample) |
| DK (1) | DK2126092T3 (enExample) |
| ES (1) | ES2688623T3 (enExample) |
| IL (1) | IL200593B (enExample) |
| WO (1) | WO2008132568A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10259860B2 (en) * | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| EA201500156A3 (ru) | 2008-01-03 | 2017-09-29 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| AU2010230563A1 (en) | 2009-04-02 | 2011-09-22 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain Fab fragments |
| US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体 |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
| RU2013141078A (ru) | 2011-02-28 | 2015-04-10 | Ф. Хоффманн-Ля Рош Аг | Одновалентные антигенсвязывающие белки |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
| CN103857699B (zh) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| EP2751135A4 (en) | 2011-08-31 | 2015-06-03 | Indi Molecular Inc | VEGF SPECIFIC CAPTURING AGENTS, COMPOSITIONS CONTAINING SAME AND METHODS OF USE AND PRODUCTION THEREOF |
| JP6486686B2 (ja) | 2012-02-10 | 2019-03-20 | ジェネンテック， インコーポレイテッド | 単鎖抗体及び他のヘテロ多量体 |
| JP6309002B2 (ja) | 2012-06-27 | 2018-04-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用 |
| CN110256567B (zh) | 2012-06-27 | 2023-04-25 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途 |
| NZ702201A (en) | 2012-07-13 | 2018-01-26 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| GB201223053D0 (en) | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
| EA201890895A1 (ru) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
| KR102060187B1 (ko) * | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
| EP3381940B1 (en) | 2013-07-29 | 2022-09-07 | Samsung Electronics Co., Ltd. | Anti-ang2 antibody |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| CA2922912A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
| KR20150063728A (ko) * | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-C/항 Ang2 이중 특이 항체 |
| WO2015140638A1 (en) * | 2014-03-18 | 2015-09-24 | Korea Advanced Institute Of Science And Technology (Kaist) | Glycosylated vegf decoy receptor fusion protein |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| WO2017197199A1 (en) * | 2016-05-13 | 2017-11-16 | Askgene Pharma Inc. | Novel angiopoietin 2, vegf dual antagonists |
| JP7107914B2 (ja) | 2016-07-20 | 2022-07-27 | アイポイント ファーマシューティカルズ， インコーポレイテッド | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| WO2020037309A1 (en) * | 2018-08-17 | 2020-02-20 | Trican Biotechnology Co., Ltd. | Anti-angiogenesis fusion protein and uses thereof |
| CN113164597B (zh) | 2018-09-24 | 2025-02-28 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| TW202128991A (zh) | 2019-12-06 | 2021-08-01 | 美商再生元醫藥公司 | 抗ｖｅｇｆ蛋白組成物及其製備方法 |
| KR102426802B1 (ko) * | 2019-12-23 | 2022-07-28 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| JP2024514072A (ja) * | 2021-03-31 | 2024-03-28 | ハングズホウ エクセジェネシス バイオ エルティーディー． | Ｖｅｇｆ及びアンジオポエチンを標的とする融合分子及びその使用 |
| AU2022325360A1 (en) * | 2021-08-09 | 2024-03-21 | Yuanpu Biotechnology (Wuhan) Co., Ltd. | Bispecific fusion polypeptide and application thereof |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN114262683B (zh) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用 |
| WO2023199951A1 (ja) * | 2022-04-13 | 2023-10-19 | 株式会社セルージョン | 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169939A (en) * | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6521424B2 (en) * | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| CA2714081C (en) * | 2000-02-10 | 2013-08-06 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| DK1292335T3 (da) * | 2000-06-23 | 2007-09-17 | Bayer Schering Pharma Ag | Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II) |
| EP1427829A4 (en) * | 2001-08-31 | 2005-10-12 | Abmaxis Inc | MULTIVALENT PROTEIN CONJUGATE WITH SEVERAL LIGANDEN BINDING RECORDORDOMAS |
| US7081443B2 (en) * | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| WO2005021578A2 (en) * | 2004-08-25 | 2005-03-10 | Amprotein Corporation | A novel chimeric polypeptide and use thereof |
| WO2006043972A1 (en) | 2004-10-12 | 2006-04-27 | Amprotein Corporation | Chimeric protein |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| US10259860B2 (en) * | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| KR102060187B1 (ko) * | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
-
2007
- 2007-10-31 US US11/932,021 patent/US10259860B2/en active Active
-
2008
- 2008-02-27 WO PCT/IB2008/000901 patent/WO2008132568A2/en not_active Ceased
- 2008-02-27 CN CN201810332855.2A patent/CN108546301B/zh active Active
- 2008-02-27 ES ES08788817T patent/ES2688623T3/es active Active
- 2008-02-27 JP JP2009551284A patent/JP5564268B2/ja active Active
- 2008-02-27 AU AU2008243928A patent/AU2008243928B2/en active Active
- 2008-02-27 EP EP08788817.8A patent/EP2126092B1/en active Active
- 2008-02-27 CN CN200880013111.9A patent/CN101679988B/zh active Active
- 2008-02-27 DK DK08788817.8T patent/DK2126092T3/en active
- 2008-02-27 KR KR1020097020284A patent/KR101220245B1/ko active Active
- 2008-02-27 CA CA2679658A patent/CA2679658C/en active Active
-
2009
- 2009-08-26 IL IL200593A patent/IL200593B/en active IP Right Grant
-
2014
- 2014-03-05 JP JP2014042371A patent/JP5952847B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518871A5 (enExample) | ||
| Qi et al. | Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1 | |
| IL264057A (en) | Antibodies and vaccines for use in the treatment of ROR1 cancers and inhibition of metastases | |
| US11827697B2 (en) | Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof | |
| Schaefer et al. | Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies | |
| Xu et al. | Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system | |
| JP2011024595A5 (enExample) | ||
| JP2017515460A5 (enExample) | ||
| CN105175545A (zh) | 一种抗vegf-抗pd-1双功能抗体及其应用 | |
| RU2013140472A (ru) | Слитый белок антиангиогенного индуцирующего фактора и его применение | |
| CN105837688B (zh) | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 | |
| JP2011137003A5 (enExample) | ||
| RU2015123032A (ru) | Иммунотерапия с применением связывающих агентов | |
| JP2014518615A5 (enExample) | ||
| RU2002100071A (ru) | Модифицированные химерные полипептиды с улучшенными фармакокинетическими свойствами | |
| MX353813B (es) | Moleculas de union a vegf. | |
| JP2013538566A5 (enExample) | ||
| AU2018303254B2 (en) | Generating multispecific antibody mixtures and methods of uses thereof | |
| JP2014513941A5 (enExample) | ||
| RU2013140184A (ru) | Fgf-r-fc слитый белок и его использование | |
| EP4303231A1 (en) | Bispecific antibody | |
| Zettlitz et al. | ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody | |
| CN109705213B (zh) | 抗金黄色葡萄球菌毒素抗体及其用途 | |
| Cai et al. | Construction of a disulfide‐stabilized diabody against fibroblast growth factor‐2 and the inhibition activity in targeting breast cancer | |
| AU2016347610A1 (en) | Polypeptides against IL-23 |